SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (date of earliest event reported): January 9, 2008



                       WHISPERING OAKS INTERNATIONAL, INC.
            ----------------- -------------------------------------
                 (Name of Small Business Issuer in its charter)

         Texas                         0-26947                 75-2742601
-------------------------         ------------------       ------------------
(State or other jurisdiction     (Commission File No.)       (IRS Employer
of incorporation)                                          Identification No.)


                           7080 River Road, Suite 215
                   Richmond, British Columbia , Canada V6X 1X5
               --------------------------------------------------
          (Address of Principal Executive Offices, including Zip Code)


Registrant's telephone number, including area code:    (866) 884-8669




                                       N/A
                  --------------------------------------------
          (Former name or former address if changed since last report)




<PAGE>


Item 1.01.  Entry into a Material Definitive Agreement

     On January 9, 2008,  Biocurex signed a licensing  agreement with Inverness
Medical Innovations,  Inc. Under terms of the agreement,  Inverness obtained the
worldwide,  semi-exclusive  rights to  commercialize  products using  Biocurex's
RECAF technology.  The agreement  includes payment to Biocurex of up-front fees,
annual minimum royalties and royalties on any product sales.

     Inverness  may terminate  the License  Agreement on 30 days notice  written
notice to Biocurex, provided that:

     o    All initial licensing fees must nevertheless be paid; and
     o    If the License  Agreement is  terminated  by Inverness  without  cause
          after the first  commercial  sale of a product  subject to the License
          Agreement, an amount equal to the greater of $300,000 or the royalties
          payable to Biocurex  during the twelve  month period prior to the date
          of termination.



                                       2

<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date: January 15, 2008

                                    WHISPERING OAKS INTERNATIONAL INC.


                                     By: /s/ Dr. Ricardo Moro
                                        -------------------------------------
                                        Dr. Ricardo Moro, President
[{"type": "8-K", "sequence": "1", "filename": "inverness8k1-08.txt", "secsgml_size_bytes": 2983}]
{"company-data": {"conformed-name": "WHISPERING OAKS INTERNATIONAL INC", "cik": "0001092562", "assigned-sic": "3841", "irs-number": "752742601", "state-of-incorporation": "A1", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26947", "film-number": "08532920"}, "business-address": {"street1": "7080 RIVER RD", "street2": "STE 215", "city": "RICHMOND", "state": "A1", "zip": "V6X 1X5", "phone": "6042079150"}, "mail-address": {"street1": "7080 RIVER RD", "street2": "STE 215", "city": "RICHMOND", "state": "A1", "zip": "V6X 1X5"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): January 9, 2008

                       WHISPERING OAKS INTERNATIONAL, INC.
            ----------------- -------------------------------------
                 (Name of Small Business Issuer in its charter)

         Texas                         0-26947                 75-2742601
-------------------------         ------------------       ------------------
(State or other jurisdiction     (Commission File No.)       (IRS Employer
of incorporation)                                          Identification No.)

                           7080 River Road, Suite 215
                   Richmond, British Columbia , Canada V6X 1X5
               --------------------------------------------------
          (Address of Principal Executive Offices, including Zip Code)

Registrant's telephone number, including area code:    (866) 884-8669

                                       N/A
                  --------------------------------------------
          (Former name or former address if changed since last report)
Item 1.01.  Entry into a Material Definitive Agreement

     On January 9, 2008,  Biocurex signed a licensing  agreement with Inverness
Medical Innovations,  Inc. Under terms of the agreement,  Inverness obtained the
worldwide,  semi-exclusive  rights to  commercialize  products using  Biocurex's
RECAF technology.  The agreement  includes payment to Biocurex of up-front fees,
annual minimum royalties and royalties on any product sales.

     Inverness  may terminate  the License  Agreement on 30 days notice  written
notice to Biocurex, provided that:

     o    All initial licensing fees must nevertheless be paid; and
     o    If the License  Agreement is  terminated  by Inverness  without  cause
          after the first  commercial  sale of a product  subject to the License
          Agreement, an amount equal to the greater of $300,000 or the royalties
          payable to Biocurex  during the twelve  month period prior to the date
          of termination.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: January 15, 2008

                                    WHISPERING OAKS INTERNATIONAL INC.

                                     By: /s/ Dr. Ricardo Moro
                                        -------------------------------------
                                        Dr. Ricardo Moro, President